IL37 and enthesitis: The results showed that more people in the IL-23 inhibitor group recovered from enthesitis (RR = 1.50; 95%CI: 1.34–1.67; P < 0.001; I2 = 5%; Fig. 7a) and dactylitis (RR = 1.40; 95%CI: 1.22–1.61; P < 0.001; I2 = 14%; Fig. 7b) compared to the placebo group.